Hao Jiang

List of Publications by Year in Descending Order

33 papers	836 citations	19 h-index	28 g-index
34 ext. papers	900 ext. citations	3.8 avg, IF	3.43 L-index

#	Paper	IF	Citations
33	Perspectives on exploring hybrid LBA/LC-MS approach for clinical immunogenicity testing. *Bioanalysis*, **2019**, 11, 1605-1617	2.1	5
32	Concerted application of LC-MS and ligand binding assays to better understand exposure of a large molecule drug. *Bioanalysis*, **2018**, 10, 1261-1272	2.1	2
31	Semiquantification and Isotyping of Antidrug Antibodies by Immunocapture-LC/MS for Immunogenicity Assessment **2017**, 91-98		1
30	Overcoming interference with the detection of a stable isotopically labeled microtracer in the evaluation of beclabuvir absolute bioavailability using a concomitant microtracer approach. *Journal of Pharmaceutical and Biomedical Analysis*, **2017**, 143, 9-16	3.5	5
29	2017 White Paper: rise of hybrid LBA/LCMS immunogenicity assays (Part 2: hybrid LBA/LCMS biotherapeutics, biomarkers & immunogenicity assays and regulatory agenciesSinputs). *Bioanalysis*, **2017**, 9, 1895-1912	2.1	22
28	Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans. *Xenobiotica*, **2016**, 46, 52-64	2	12
27	Cynomolgus Monkey as a Clinically Relevant Model to Study Transport Involving Renal Organic Cation Transporters: In Vitro and In Vivo Evaluation. *Drug Metabolism and Disposition*, **2016**, 44, 238-49	4	24
26	A highly sensitive and selective LC-MS/MS method to quantify asunaprevir, an HCV NS3 protease inhibitor, in human plasma in support of pharmacokinetic studies. *Journal of Pharmaceutical and Biomedical Analysis*, **2016**, 119, 145-51	3.5	6
25	Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma. *Journal of Pharmaceutical and Biomedical Analysis*, **2015**, 107, 409-18	3.5	48
24	Development and characterization of a pre-treatment procedure to eliminate human monoclonal antibody therapeutic drug and matrix interference in cell-based functional neutralizing antibody assays. *Journal of Immunological Methods*, **2015**, 416, 94-104	2.5	18
23	Sensitive and accurate liquid chromatography-tandem mass spectrometry methods for quantitative determination of a novel hepatitis C NS5B inhibitor BMS-791325 and its active metabolite in human plasma and urine. *Journal of Pharmaceutical and Biomedical Analysis*, **2015**, 107, 17-23	3.5	5
22	Development and validation of an LC-MS/MS assay for the quantitation of a PEGylated anti-CD28 domain antibody in human serum: overcoming interference from antidrug antibodies and soluble target. *Bioanalysis*, **2014**, 6, 2371-83	2.1	18
21	A validated LC-MS/MS method for the simultaneous determination of BMS-791325, a hepatitis C virus NS5B RNA polymerase inhibitor, and its metabolite in plasma. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2014**, 973C, 1-8	3.2	18
20	Sensitivity-based analytical approaches to support human absolute bioavailability studies. *Bioanalysis*, **2014**, 6, 497-504	2.1	15
19	Innovative use of LC-MS/MS for simultaneous quantitation of neutralizing antibody, residual drug, and human immunoglobulin G in immunogenicity assay development. *Analytical Chemistry*, **2014**, 86, 2673-80	7.8	33
18	An exploratory universal LC-MS/MS assay for bioanalysis of hinge region-stabilized human IgG4 mAbs in clinical studies. *Bioanalysis*, **2014**, 6, 1747-58	2.1	21
17	Current advances and strategies towards fully automated sample preparation for regulated LC-MS/MS bioanalysis. *Bioanalysis*, **2014**, 6, 2441-59	2.1	29

List of Publications

16	A rugged and accurate liquid chromatography-tandem mass spectrometry method for the determination of asunaprevir, an NS3 protease inhibitor, in plasma. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2013**, 921-922, 81-6	3.2	14
15	Fully validated LC-MS/MS assay for the simultaneous quantitation of coadministered therapeutic antibodies in cynomolgus monkey serum. *Analytical Chemistry*, **2013**, 85, 9859-67	7.8	66
14	Practical and efficient strategy for evaluating oral absolute bioavailability with an intravenous microdose of a stable isotopically-labeled drug using a selected reaction monitoring mass spectrometry assay. *Analytical Chemistry*, **2012**, 84, 10031-7	7.8	33
13	A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine. *Journal of Chromatography A*, **2012**, 1245, 117-21	4.5	31
12	Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies. *Analytical Chemistry*, **2012**, 84, 4844-50	7.8	30
11	A user-friendly robotic sample preparation program for fully automated biological sample pipetting and dilution to benefit the regulated bioanalysis. *Journal of the Association for Laboratory Automation*, **2012**, 17, 211-21		18
10	A convenient strategy for quantitative determination of drug concentrations in tissue homogenates using a liquid chromatography/tandem mass spectrometry assay for plasma samples. *Analytical Chemistry*, **2011**, 83, 6237-44	7.8	22
9	A rugged and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of BMS-790052 in plasma. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2011**, 879, 2064-72	3.2	14
8	Metabolism of benzo[a]pyrene in human bronchoalveolar H358 cells using liquid chromatography-mass spectrometry. *Chemical Research in Toxicology*, **2007**, 20, 1331-41	4	62
7	Benzo[a]pyrene-7,8-dihydrodiol promotes checkpoint activation and G2/M arrest in human bronchoalveolar carcinoma H358 cells. *Molecular Pharmacology*, **2007**, 71, 744-50	4.3	27
6	Competing roles of aldo-keto reductase 1A1 and cytochrome P4501B1 in benzo[a]pyrene-7,8-diol activation in human bronchoalveolar H358 cells: role of AKRs in P4501B1 induction. *Chemical Research in Toxicology*, **2006**, 19, 68-78	4	42
5	Quantification of benzo[a]pyrene diol epoxide DNA-adducts by stable isotope dilution liquid chromatography/tandem mass spectrometry. *Rapid Communications in Mass Spectrometry*, **2006**, 20, 1369-80	2.2	36
4	Competing roles of cytochrome P450 1A1/1B1 and aldo-keto reductase 1A1 in the metabolic activation of (+/-)-7,8-dihydroxy-7,8-dihydro-benzo[a]pyrene in human bronchoalveolar cell extracts. *Chemical Research in Toxicology*, **2005**, 18, 365-74	4	51
3	Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics. *Journal of Clinical Pharmacology*, **2004**, 44, 1260-72	2.9	26
2	Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. *British Journal of Pharmacology*, **2004**, 141, 616-23	8.6	46
1	Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography-tandem mass spectrometry. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2002**, 769, 169-76	3.2	34